Tuesday 13 October 2026
Export ASMB’s income statement to Excel — free account
Assembly Biosciences, Inc.
ASMB Healthcare Biotechnology
Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024. In the quarter to June 2026, revenue grew 38.9%, EPS grew 85.0% and free cash flow grew 7.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
20.69
2.08
−9.13%
Follow ASMB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
26.94 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.92 | 6.60 | 5.27 | 8.73 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(33.45) | (21.22) | 26.78 | (21.46) | |
P/B ratio |
1.70 | 2.36 | 1.84 | 1.78 | |
Price to Tangible BV |
1.96 | 2.99 | 2.31 | 2.30 | |
EV/Sales |
2.64 | 3.41 | 1.84 | 2.48 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.14) | (6.10) | (3.24) | (1.65) | |
EV/FCF |
(5.13) | (6.08) | (3.24) | (1.65) | |
Quick Ratio |
13.70 | 6.49 | 5.11 | 4.37 | |
Current Ratio |
13.99 | 6.65 | 5.22 | 4.44 | |
Net Debt/EBITDA |
45.17 | 18.68 | (13.06) | 20.25 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.36 | 0.43 | 0.38 | 0.22 | |
Operating CF/Net income |
4.02 | 2.43 | 0.64 | 1.65 | |
Capex/Depreciation |
0.00 | 0.02 | 0.03 | 0.07 | |
Interest Coverage |
2.55 | — | — | — | |
Research and Development Expense of Revenue |
111.54% | 181.42% | 40.62% | 153.74% | |
Selling, General and Administrative Expense of Revenue |
35.90% | 57.02% | 12.76% | 47.13% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
18.06% | 13.59% | 3.44% | 15.48% | |
Graham Net Nets |
0.58 | 0.42 | 0.53 | 0.55 | |
Graham Number |
19.29 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
3.71% | (0.40%) | (2.18%) | (18.71%) | |
Free Cash Flow Yield |
(7.44%) | (8.49%) | (10.79%) | (17.18%) | |
Revenue per Share |
0.71 | 0.49 | 3.79 | 0.85 | |
Operating CF per Share |
(0.82) | (1.31) | 1.27 | (1.19) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.82) | (1.31) | 1.27 | (1.20) | |
Cash per Share |
16.99 | 13.41 | 22.13 | 18.33 | |
Shareholders Equity per Share |
16.21 | 11.75 | 18.44 | 14.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
16.21 | 11.75 | 18.44 | 14.40 | |
Free Cash Flow |
(15.49) | (22.12) | 14.21 | (15.17) | |
Working Capital |
304.53 | 197.62 | 205.77 | 183.43 | |
Capital Expenditures |
0.00 | (0.02) | (0.02) | (0.04) | |
Net Current Asset Value |
302.80 | 195.72 | 203.71 | 179.51 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.43 | 0.25 | 0.54 | 0.63 | |
Average Payables |
0.96 | 1.00 | 0.88 | 1.51 | |
Average Assets |
205.81 | 167.26 | 188.38 | 170.13 | |
Average Common Equity |
161.87 | 112.87 | 120.06 | 104.35 |
Columns are period end dates